Clinical Trial

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2024 (before its estimated May 19, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-10.
Status change: Not Yet Recruiting → Recruiting 2024-05-26
Trial Details
NCT Number NCT06415669
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 30 participants
Start Date 2024-05-19
Primary Completion 2026-05-19 (estimated)
Study Completion 2027-05-19 (estimated)
Updated on ClinicalTrials.gov 2024-05-29